BeiGene, Ltd.
06160
2023 3 31
13.09
571 XIVA
2023 3 31
2023 3 31
2023 2023
2023 5 4
1
1995 (Private Securities Litigation
Reform Act of 1995)
10-K
2023 5 4
Margaret Han Dugan Donald W. Glazer
Michael Goller Anthony C. Hooper Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2023
2023 4.103 2.616
56.9%
(CLL) (SLL)
2023 2.114
2023 5 4
BGNE 06160 688235
2023
(John V. Oyler)
BTK
CLL
(Julia Wang)
2023
2023 3 31 4.478 2022
3.066
2023 3 31 4.103 2022
2.616
2023
2.114
1.043
2023
1.149
8,760
2023 3,640
2,990
2023 3 31 3,750
2021
2021
4,510
3
2023 8,180
6,520
2023 80.1%
75.1%
2023 3 31 7.373
2022 6.847
2023 3 31 4.086
3.899
2023 3,400
3,090
(SG&A) 2023 3 31 SG&A
3.285 2.946 SG&A
2023 2022
SG&A 4,140 3,470
2023 3 31 3.484
0.26 (ADS) 3.34 2022
4.352 0.33 ADS 4.25
2023
2023 3 31 38
2022 12 31 45
2023 3 31 5.638
3.484
2.941 7,870
1.256 1,990
2022 3 31 2.366
4.352 8,090
3
1.177
4,510 1,130
4
2023 57%
2023
2.114
103% CLL/SLL
2023
1.388 104%
FDA
2023 4,810
44%
2023
1.149
31%
(BTK)
BTK
65
29
4,900
3 ALPINE
R/R CLL
(FDA)
CLL/SLL
R/R (FL)
(sNDA) R/R CLL PFS
ACCESS (ACCESS consortium)
R/R FL sNDA
2023 30
5
IgG4 PD-1
Fcγ
10
31 12,100
2023 (AACR) RATIONALE-
302(NCT03430843) RATIONALE-304(NCT03663205) RATIONALE-
306(NCT03783442) RATIONALE-307(NCT03594747)
3
FDA
(BLA)
(BGB-A1217) Fc TIGIT
20 1,700
(NSCLC) 2
(NCT05014815)
BGB-11417 BCL-2
B
(AML) (MDS)
(MM) BGB-11417
7 430
BGB-11417 R/R (MCL)(NCT05471843) R/R
CLL/SLL(NCT05479994) 2
BGB-A445 OX40
1 (NCT04215978)
BGB-B167 CEA x 4-1BB
CEA
(CRC)
BGB-A425
NSCLC
TIM-3
6
BGB-15025
1(HPK1)
BGB-16673 (CDAC) BTK
B
BGB-24714 (SMAC)
2023 AACR
BGB-10188
PI3Kδ
BGB-23339 2(TYK2)
SpringWorks Therapeutics AACR B-RAF
lifirafenib(BGB-283) SpringWorks MEK mirdametinib
RAS RAF MAPK 1b
MapKure SpringWorks AACR RAF
brimarafenib (BGB-3245) MAPK
1a/b
LAG-3 LBL-007
CRC 2
(NCT05609370)
L B L -007
BGB-A445
NCT05635708 NCT05577702
100 9.3
54,000 2023 10,000
7
(ADC)
2024
2025
55.9 5.2
6 2023
10
FDA (EMA) R/R CLL
R/R CLL PFS
CLL/SLL WM sNDA
2023
CLL sNDA 2023
2023 ASCO
R/R B
1
ROSEWOOD
NMPA
(BLA)
ESCC
2023
2023
8
(TGA)
NSCLC
ESCC BLA 2023
(Medsafe)
NSCLC ESCC BLA
(MFDS)
ESCC BLA
(Anvisa)
NSCLC
ESCC BLA
FDA
ESCC BLA 2023
EMA
NSCLC ESCC
2023
NSCLC
ESCC
ESCC NSCLC
2023 FDA
ESCC
2023
ESCC BLA
2023
2023 ASCO RATIONALE 301
BGB-11417 BCL-2
2023
CLL
2023 ASCO 1 BGB-11417
B
9
TIGIT
2023 2
PD-(L)1 ESCC(NCT04732494)
(NCT04948697)
NSCLC(NCT05014815)
2023 NSCLC 3 AdvanTIG-302
2023 ASCO 1b AdvanTIG-105
BGB-16673(BTK CDAC)
2023 B 1 NCT05006716
NCT05294731
BGB-A445 OX40
2023 1 (NCT04215978)
2023 ASCO OX40 BGB-A445
1
BGB-15025 HPK1
2023
(NCT04649385)
2023 ASCO HER2
zanidatamab HER2 1b/2
zanidatamab HER2
2b HERIZON-BTC-01
10
2023 2022
3 31 12 31
$3,837,823 $4,540,288
309,628 173,168
296,995 282,346
925,404 845,946
5,956,775 6,379,290
241,360 294,781
417,922 467,352
222,822 255,887
276,562 293,960
488,106 538,117
1,799,469 1,995,935
$4,157,306 $4,383,355
11
ADS ADS
3 31 3
2023 2022 1
$410,291 $261,573
37,510 45,053
447,801 306,626
81,789 65,237
408,584 389,915
328,499 294,573
187 188
819,059 749,913
(371,258) (443,287)
16,016 10,071
18,303 11,967
(336,939) (421,249)
11,492 13,949
(348,431) (435,198)
$(0.26) $(0.33)
1,354,164,760 1,332,017,262
ADS
$(3.34) $(4.25)
ADS
104,166,520 102,462,866
1
2022
2023 3 31 10-Q 1.
2.
12
9,400
http://www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
10-K
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
Pharmacyclics LLC
13